This week, Mark and Margaret speak with Dr. Eric Green, Director of the National Human Genome Research Institute, one of the 27 Institutes at NIH. They have launched a new program called Big Data to Knowledge, or BD2K, which seeks to create better platforms for storing and sharing the large volumes of big data that have emerged in the world of scientific research since the mapping of the human genome. Dr. Green also talks about the threats to future research from young scientists struggling to achieve in a climate of reduced grant funding nationwide.
Converting Big Data into Knowledge: Updates from the National Human Genome Research Institute

Transcript
Converting Big Data into Knowledge: Updates from the National Human Genome Research Institute
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
This week, Mark and Margaret speak with Dr. Eric Green, Director of the National Human Genome Research Institute, one of the 27 Institutes at NIH. They have launched a new program called Big Data to Knowledge, or BD2K, which seeks to create better platforms for storing and sharing the large volumes of big data that have emerged in the world of scientific research since the mapping of the human genome. Dr. Green also talks about the threats to future research from young scientists struggling to achieve in a climate of reduced grant funding nationwide.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
NYHA FC and Finerenone Response: Clinical Trial Insights
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?